Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,693
datasets available to search
ShareScore release 0.9.0
Dataset results
3,693 results for “cardiovascular”
Cardiovascular contributions and energetic costs of thermoregulation in ectothermic vertebrates
<p>Unfiltered data used in the manuscript with file descriptions. Includes R script and example datasets for reproducing figure 1, as well as animating figure 1 for the box turtle and painted turtle (body temperature - black solid line, ambient temperature - black dotted line, and heart rate - red solid line).</p>
Data set related to the article: "The Role of BPIFB4 in Immune System and Cardiovascular Disease: The Lesson from Centenarians."
<p>Abstract:</p> <p>Recent discoveries have shed light on the participation of the immune system in the physio pathology of the car- diovascular system underpinning the importance of keeping the balance of the first to preserve the latter. Aging, along with other risk factors, can challenge such balance triggering the onset of cardiovascular diseases.</p> <p>Among several mediators ensuring the proper cross-talk between the two systems, bactericidal/permeability- increasing fold-containing family B member 4 (BPIFB4) has been shown to have a pivotal role, also by sustaining important signals such as eNOS and PKC-alpha.</p> <p>In addition, the Longevity-associated variant (LAV), which is an haplotype allele in BPIFB4 characterized by 4 missense polymorphisms, enriched in homozygosity in Long Living Individuals (LLIs), has been shown to be efficient, if admin- istered systemically through gene therapy, in improving many aspects of cardiovascular diseases (CVDs). This occurs mainly through a fine immune system remodeling across: 1) a M2 macrophage polarizing effect, 2) a favorable redistri- bution of the circulating monocyte cell subsets and 3) the reduction of T-cell activation. Furthermore, LAV-BPIFB4 treat- ment induced a desirable recovery of the inflammatory balance by mitigating the pro-inflammatory factor levels and enhancing the anti-inflammatory boost through a mechanism that is partially dependent on SDF-1/CXCR4 axis.</p> <p>Importantly, the remarkable effects of LAV-BPIFB4 treatment, which translates in increased BPIFB4 circulating levels, mirror what occurs in long-living individuals (LLIs) in whom the high circulating levels of BPIFB4 are protective from age-related and CVDs and emphasize the reason why LLIs are considered a model of successful aging. Here, we review the mechanisms by which LAV-BPIFB4 exerts its immunomodulatory activity in improving the cardiovascular-immune system dialogue that might strengthen its role as a key mediator in CVDs.</p>
Rhythm control and cardiovascular or cerebrovascular out-comes in patients with atrial fibrillation: A study of the CODE-AF registry
<p><strong>SUPPLEMENTARY MATERIAL</strong></p> <p> </p> <p><strong><em>Rhythm control and cardiovascular or cerebrovascular outcomes in patients with atrial fibrillation: A study of the CODE-AF registry</em></strong></p> <p> </p> <p>Ho Gi Chung, MD; Junbeom Park; Jin-Kyu Park; Ki-Woon Kang; Jaemin Shim; Jin-Bae Kim; Jun Kim; Eue-Keun Choi; Hyung Wook Park; Young Soo Lee; Boyoung Joung</p> <table> <tbody> <tr> <td> <p><strong>Supplementary Table 1.</strong> Subgroup analysis of primary outcome in rate- and rhythm-control group before overlap weighting.</p> </td> </tr> </tbody> </table> <table> <tbody> <tr> <td> <p><strong>Supplementary Figure 1. </strong>Cumulative incidence of primary outcome in rhythm and rate control treatment groups before overlap weighting.</p> </td> </tr> </tbody> </table> <table> <tbody> <tr> <td> <p><strong>Supplementary Figure 2. </strong>Cumulative incidence of secondary outcomes in rhythm and rate control treatment groups before overlap weighting.</p> </td> </tr> </tbody> </table>
Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in Southeastern China
<p class="MsoNormal"><span>Objective: To evaluate the associations between serum uric acid (SUA) levels and cardiovascular disease (CVDs) risk factors, focusing on potential sex-specific differences.</span></p> <p class="MsoNormal"><span>Design: A retrospective cohort study.</span></p> <p class="MsoNormal"><span>Setting: A large community-based survey was conducted every two years from 2010 to 2018 in Hangzhou, Zhejiang Province, Southeastern China.</span></p> <p class="MsoNormal"><span>Participants: 6119 participants aged 40 years and above who underwent at least three times of physical examinations were enrolled. </span></p> <p class="MsoNormal"><span>Methods: Participants were categorized into four groups (Q1-Q4) based on baseline SUA quartiles within the normal range, with hyperuricemia (HUA) as the fifth group. The Q1 was the reference. By stratifying participants by gender, the relationships between SUA levels and systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and total cholesterol (TC) were investigated using linear regression models in the generalized estimating equation (GEE). Additionally, the associations of elevated SUA levels and HUA with hypertension, hyperglycemia, and dyslipidemia were correspondingly examined using multivariate logistic regression models.</span></p> <p class="MsoNormal"><span>Results: After adjusting for confounding variables, we found positive associations between SUA levels and SBP, DBP, FBG, and TC in women, and with TC in men (P < 0.01). Likewise, Elevated SUA quartiles and HUA were linked to increased dyslipidemia risk in both sexes, and increased hyperglycemia risk only in women, with HRs (95%CI) of 1.64 (1.05-2.55) and 2.37 (1.47-3.81) in the Q4 and HUA group, respectively. Women with HUA had higher hypertension risk (HR=1.45, 95% CI 1.21-1.73), while no such association was observed in men. Stratified analyses revealed significant associations between elevated SUA levels and CVDs risk factors in postmenopausal and non-obese women.</span></p> <p class="MsoNormal"><span>Conclusions: Elevated SUA levels increase the risk of dyslipidemia in both sexes. SUA levels within normal-range and HUA are positively associated with hyperglycemia and hypertension in postmenopausal women, but not in men.</span></p>
DESFECHOS CLÍNICOS ASSOCIADAS A INTERFERÊNCIAS CARDIOVASCULARES SECUNDÁRIAS À DOENÇA DE CHAGAS EM UM PACIENTE IDOSO: RELATO DE CASO
<p><strong>Introdução:</strong> A Doença de Chagas (DC) trata-se de uma doença crônica, de carater infecto-parasitária, com alta prevalência, podendo comunicar-se aos humanos por meio do seu agente etiológico é o protozoário <i>Trypanosoma Cruzi, </i>sendo decurso clínico da patologia bifásico, mesclando por uma fase aguda e uma fase crônica. <strong>Objetivo: </strong>Descrever informações a cerca de um caso clínico de uma paciente com um bloqueio secundário a uma infecção por doença de chagas. <strong>Relato de caso:</strong> Relata-se o caso de paciente do sexo feminino, 71 anos, com o diagnóstico de cardiopatia da doença de Chagas, com história de síncope por provável arritmia e sinais de insuficiência cardíaca. <strong>Discussão:</strong> Com histórico de arritmias ventriculares, síncopes recorrentes acompanhada de picos hipertensivos, palpitações e lipotimias, as quais, são manifestações cardíacas da Doença de Chagas, fundamentando com os resultados dos exames complementares realizados pela paciente. <strong>Conclusão:</strong> Revelou-se a importância da identificação dos sintomas e o diagnóstico precoce da infecção para impedir as possíveis complicações, a evolução da doença e reforçar a indispensabilidade de orientação dos profissionais de saúde para o reconhecimento precoce da doença e tratamento clínico apropriado.</p>
Emergent factors of cardiovascular risk epidemiology and global cardiovascular risk
<p><strong>Introduction:</strong> Risk factors determine important clinical implications for cardiovascular prevention. <strong>Objective:</strong> Determine the epidemiology of emerging cardiovascular risk factors and global cardiovascular risk. Method: an observational, analytical, longitudinal and retrospective, case/control investigation was carried out from the individuals evaluated in the cardiology clinic of the Darío Calzadilla Angulo Polyclinic, Banes municipality, Holguín province during May 2021- May 2022. By sampling simple random, the sample was obtained (113 cases). The bioethical requirements were met. Inclusion/exclusion criteria were applied. The following statisticians were used: Chi square, Odd Ratio (OR), including p and confidence interval. The variables were operationalized: sex, age, risk factors, cardiovascular disease, and global cardiovascular risk. The control group was formed at a ratio of 2:1. <strong>Results:</strong> The age groups 60-69 years and 40-49 years prevailed. The female sex predominated. The clinical forms of ischemic cardiomyopathy and arrhythmias had a higher incidence. The associated diseases expressed a significant statistical association for cardiovascular disease, with a predominance of arterial hypertension (OR=2.38), obesity (OR=1.64) and diabetes mellitus (OR=1.79); with increased risk. Emerging cardiovascular risk factors expressed a very significant statistical association for cardiovascular disease with a predominance of high triglyceride quantification values (X2=24.8 OR=3.93 95% CI (2.25;6.86) p=0.000). High global cardiovascular risk was more frequent. <strong>Conclusions:</strong> Emerging cardiovascular risk factors and global cardiovascular risk are mostly modifiable.</p><p><strong>Keyword:</strong> CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; RISK FACTOR'S; GLOBAL CARDIOVASCULAR RISK</p>
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
ClinicalTrials.gov study NCT03385239. IPD Sharing: NO. Countries: 2. Publications: 1.
Subclinical Cardiovascular Disease in Psoriatic Disease
ClinicalTrials.gov study NCT03228017. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1
ClinicalTrials.gov study NCT00218439. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease
ClinicalTrials.gov study NCT00603590. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overw
ClinicalTrials.gov study NCT02019264. IPD Sharing: Not stated. Countries: 8. Publications: 4.
Frequency-Dependent Effects of Auricular Vagus Nerve Stimulation on Autonomic and Cardiovascular Parameters
ClinicalTrials.gov study NCT07274332. IPD Sharing: NO. Countries: 1. Publications: 7.
Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise
ClinicalTrials.gov study NCT01679600. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Effect of Efpeglenatide on Cardiovascular Outcomes
ClinicalTrials.gov study NCT03496298. IPD Sharing: NO. Countries: 28. Publications: 5.
Sitting Interruption and Whole-body Cardiovascular Health
ClinicalTrials.gov study NCT05316571. IPD Sharing: YES. Countries: 1. Publications: 1.
Platelet Activity in Vascular Surgery and Cardiovascular Events
ClinicalTrials.gov study NCT02106429. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation
ClinicalTrials.gov study NCT03026777. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
ClinicalTrials.gov study NCT04847232. IPD Sharing: YES. Countries: 26. Publications: 2.
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
ClinicalTrials.gov study NCT06930885. IPD Sharing: YES. Countries: 1. Publications: 4.
SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk
ClinicalTrials.gov study NCT03151343. IPD Sharing: NO. Countries: 1. Publications: 25.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.